RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ALX Oncology Holdings Stock

ALX Oncology Holdings Net Income 2024

ALX Oncology Holdings Net Income

-148.26 M USD

Ticker

ALXO

ISIN

US00166B1052

WKN

A2P79Z

In 2024, ALX Oncology Holdings's profit amounted to -148.26 M USD, a -7.8% increase from the -160.81 M USD profit recorded in the previous year.

The ALX Oncology Holdings Net Income history

YEARNET INCOME (undefined USD)
2029e122.11
2028e9.15
2027e-152.24
2026e-126.96
2025e-134.7
2024e-148.26
2023-160.81
2022-123.48
2021-83.46
2020-50.94
2019-23.27
2018-17.4

ALX Oncology Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ALX Oncology Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ALX Oncology Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ALX Oncology Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ALX Oncology Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ALX Oncology Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ALX Oncology Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ALX Oncology Holdings’s growth potential.

ALX Oncology Holdings Revenue, EBIT and net profit per share

DateALX Oncology Holdings RevenueALX Oncology Holdings EBITALX Oncology Holdings Net Income
2029e259.28 M undefined-14.95 M undefined122.11 M undefined
2028e156.18 M undefined-92.84 M undefined9.15 M undefined
2027e54.4 M undefined-169.97 M undefined-152.24 M undefined
2026e3.52 M undefined-176.85 M undefined-126.96 M undefined
2025e0 undefined-150.76 M undefined-134.7 M undefined
2024e0 undefined-145.48 M undefined-148.26 M undefined
20230 undefined-170.28 M undefined-160.81 M undefined
20220 undefined-127.44 M undefined-123.48 M undefined
20210 undefined-83.56 M undefined-83.46 M undefined
20201.18 M undefined-43.66 M undefined-50.94 M undefined
20194.8 M undefined-19.18 M undefined-23.27 M undefined
20182.07 M undefined-13.68 M undefined-17.4 M undefined

ALX Oncology Holdings stock margins

The ALX Oncology Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ALX Oncology Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ALX Oncology Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ALX Oncology Holdings's sales revenue. A higher gross margin percentage indicates that the ALX Oncology Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ALX Oncology Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ALX Oncology Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ALX Oncology Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ALX Oncology Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ALX Oncology Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ALX Oncology Holdings Margin History

ALX Oncology Holdings Gross marginALX Oncology Holdings Profit marginALX Oncology Holdings EBIT marginALX Oncology Holdings Profit margin
2029e9.32 %-5.77 %47.1 %
2028e9.32 %-59.45 %5.86 %
2027e9.32 %-312.42 %-279.84 %
2026e9.32 %-5,025.55 %-3,607.72 %
2025e9.32 %0 %0 %
2024e9.32 %0 %0 %
20239.32 %0 %0 %
20229.32 %0 %0 %
20219.32 %0 %0 %
20209.32 %-3,700 %-4,316.95 %
20199.17 %-399.58 %-484.79 %
20189.18 %-660.87 %-840.58 %

ALX Oncology Holdings Aktienanalyse

What does ALX Oncology Holdings do?

ALX Oncology Holdings Inc is a biopharmaceutical company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. The company was founded in 2015 and is headquartered in Burlingame, California. It is listed on the NASDAQ stock exchange under the ticker symbol "ALXO." History ALX Oncology Holdings Inc was founded by Therese S. Wagner, a respected oncologist with extensive experience in cancer research. The company began its activities with a strong vision focused on developing targeted and effective treatments for cancer patients. Business Model ALX Oncology Holdings Inc is working on the development of immunotherapy products based on two mechanisms of action - inhibition of the CD47 molecule and activation of the myeloid cells of the immune system. The goal is to eliminate cancer cells by enabling them to be recognized and attacked by the immune system. This business model has the potential to improve both the effectiveness and versatility of cancer treatment. Divisions ALX Oncology Holdings Inc operates in several areas, including: Main products: • ALX148 - A monoclonal antibody that acts as a CD47 inhibitor • ALX148-Bispecifics - Two binding domains that contribute to the activation of the myeloid cells of the immune system In addition, ALX Oncology Holdings Inc collaborates with various partners to develop new drugs and therapies. These partnerships include both academic institutions and pharmaceutical companies. Products ALX148 is the flagship product of ALX Oncology. It is a monoclonal antibody that inhibits the CD47 molecule found on the surface of cancer cells, preventing their recognition by the immune system. By inhibiting CD47, the immune system can recognize and destroy cancer cells. ALX148-Bispecifics are antibody-drug conjugates (ADC) and bispecific antibodies (BsAb) that have been developed to activate the myeloid cells in the immune system by combining CD47 inhibitory capabilities with the activation of macrophage-associated ligands (CD40 and CD80). This results in a stronger immune response to cancer cells, leading to their destruction. Summary ALX Oncology Holdings Inc is a biotechnology company specializing in the development and commercialization of immunotherapy products for the treatment of cancer. Their products, ALX148 and ALX148-Bispecifics, inhibit the CD47 molecule and activate the immune system to fight cancer cells. The company collaborates with various partners and has the potential to provide new hope for people with cancer. ALX Oncology Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding ALX Oncology Holdings's Profit Margins

The profit margins of ALX Oncology Holdings represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of ALX Oncology Holdings's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating ALX Oncology Holdings's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

ALX Oncology Holdings's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When ALX Oncology Holdings’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about ALX Oncology Holdings stock

How much profit has ALX Oncology Holdings made this year?

ALX Oncology Holdings has made -148.26 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -7.8% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does ALX Oncology Holdings publish its earnings?

ALX Oncology Holdings publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of ALX Oncology Holdings?

The profits of ALX Oncology Holdings are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of ALX Oncology Holdings?

You can learn more about the earnings of ALX Oncology Holdings by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does ALX Oncology Holdings pay?

Over the past 12 months, ALX Oncology Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ALX Oncology Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of ALX Oncology Holdings?

The current dividend yield of ALX Oncology Holdings is .

When does ALX Oncology Holdings pay dividends?

ALX Oncology Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ALX Oncology Holdings?

ALX Oncology Holdings paid dividends every year for the past 0 years.

What is the dividend of ALX Oncology Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ALX Oncology Holdings located?

ALX Oncology Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von ALX Oncology Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ALX Oncology Holdings from 12/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.

When did ALX Oncology Holdings pay the last dividend?

The last dividend was paid out on 12/17/2024.

What was the dividend of ALX Oncology Holdings in the year 2023?

In the year 2023, ALX Oncology Holdings distributed 0 USD as dividends.

In which currency does ALX Oncology Holdings pay out the dividend?

The dividends of ALX Oncology Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ALX Oncology Holdings

Our stock analysis for ALX Oncology Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ALX Oncology Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.